Andrew J. Geall
Oprichter bij Replicate Bioscience, Inc.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Michael Ehlers | M | - |
Replicate Bioscience, Inc.
Replicate Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Replicate Bioscience, Inc. is a clinical-stage biopharmaceutical company based in San Diego, CA. The company focuses on creating novel oncology treatments to prevent drug resistance using its synrgy technology. Replicate aims to enhance the effectiveness of many immuno-oncology regimens in early stages of care and is developing its own pipeline of immuno-oncology products in breast, lung, and prostate cancers. Replicate is differentiated by a team of srrna experts, a customizable library of synthetic srrna vectors, and end-to-end development capabilities. The company harnesses the body's natural protein-making power and uses synthetic biology to design unique self-replicating rnas (srrnas) that can direct that power to fight disease. The company was founded by Nathaniel Whang, Zachary Hartman, Michael D. Ehlers, Herbert Kim Lyerly, Andrew J. Geall, and Nathaniel Whang has been the CEO since incorporation. | - |
Nathaniel Whang | M | - |
Replicate Bioscience, Inc.
Replicate Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Replicate Bioscience, Inc. is a clinical-stage biopharmaceutical company based in San Diego, CA. The company focuses on creating novel oncology treatments to prevent drug resistance using its synrgy technology. Replicate aims to enhance the effectiveness of many immuno-oncology regimens in early stages of care and is developing its own pipeline of immuno-oncology products in breast, lung, and prostate cancers. Replicate is differentiated by a team of srrna experts, a customizable library of synthetic srrna vectors, and end-to-end development capabilities. The company harnesses the body's natural protein-making power and uses synthetic biology to design unique self-replicating rnas (srrnas) that can direct that power to fight disease. The company was founded by Nathaniel Whang, Zachary Hartman, Michael D. Ehlers, Herbert Kim Lyerly, Andrew J. Geall, and Nathaniel Whang has been the CEO since incorporation. | - |
Seth Harrison | M | 63 |
Replicate Bioscience, Inc.
Replicate Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Replicate Bioscience, Inc. is a clinical-stage biopharmaceutical company based in San Diego, CA. The company focuses on creating novel oncology treatments to prevent drug resistance using its synrgy technology. Replicate aims to enhance the effectiveness of many immuno-oncology regimens in early stages of care and is developing its own pipeline of immuno-oncology products in breast, lung, and prostate cancers. Replicate is differentiated by a team of srrna experts, a customizable library of synthetic srrna vectors, and end-to-end development capabilities. The company harnesses the body's natural protein-making power and uses synthetic biology to design unique self-replicating rnas (srrnas) that can direct that power to fight disease. The company was founded by Nathaniel Whang, Zachary Hartman, Michael D. Ehlers, Herbert Kim Lyerly, Andrew J. Geall, and Nathaniel Whang has been the CEO since incorporation. | - |
Joseph Yanchik | M | 60 |
Replicate Bioscience, Inc.
Replicate Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Replicate Bioscience, Inc. is a clinical-stage biopharmaceutical company based in San Diego, CA. The company focuses on creating novel oncology treatments to prevent drug resistance using its synrgy technology. Replicate aims to enhance the effectiveness of many immuno-oncology regimens in early stages of care and is developing its own pipeline of immuno-oncology products in breast, lung, and prostate cancers. Replicate is differentiated by a team of srrna experts, a customizable library of synthetic srrna vectors, and end-to-end development capabilities. The company harnesses the body's natural protein-making power and uses synthetic biology to design unique self-replicating rnas (srrnas) that can direct that power to fight disease. The company was founded by Nathaniel Whang, Zachary Hartman, Michael D. Ehlers, Herbert Kim Lyerly, Andrew J. Geall, and Nathaniel Whang has been the CEO since incorporation. | - |
Mohit Trikha | M | - |
Replicate Bioscience, Inc.
Replicate Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Replicate Bioscience, Inc. is a clinical-stage biopharmaceutical company based in San Diego, CA. The company focuses on creating novel oncology treatments to prevent drug resistance using its synrgy technology. Replicate aims to enhance the effectiveness of many immuno-oncology regimens in early stages of care and is developing its own pipeline of immuno-oncology products in breast, lung, and prostate cancers. Replicate is differentiated by a team of srrna experts, a customizable library of synthetic srrna vectors, and end-to-end development capabilities. The company harnesses the body's natural protein-making power and uses synthetic biology to design unique self-replicating rnas (srrnas) that can direct that power to fight disease. The company was founded by Nathaniel Whang, Zachary Hartman, Michael D. Ehlers, Herbert Kim Lyerly, Andrew J. Geall, and Nathaniel Whang has been the CEO since incorporation. | 2 jaar |
Zelanna Goldberg | M | - |
Replicate Bioscience, Inc.
Replicate Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Replicate Bioscience, Inc. is a clinical-stage biopharmaceutical company based in San Diego, CA. The company focuses on creating novel oncology treatments to prevent drug resistance using its synrgy technology. Replicate aims to enhance the effectiveness of many immuno-oncology regimens in early stages of care and is developing its own pipeline of immuno-oncology products in breast, lung, and prostate cancers. Replicate is differentiated by a team of srrna experts, a customizable library of synthetic srrna vectors, and end-to-end development capabilities. The company harnesses the body's natural protein-making power and uses synthetic biology to design unique self-replicating rnas (srrnas) that can direct that power to fight disease. The company was founded by Nathaniel Whang, Zachary Hartman, Michael D. Ehlers, Herbert Kim Lyerly, Andrew J. Geall, and Nathaniel Whang has been the CEO since incorporation. | 2 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Graham Taysom | M | - |
University of Bath
| 23 jaar |
Jee Chai Doh | M | - |
University of Bath
| 4 jaar |
Hak Kun Wong | M | 68 |
University of Bath
| 2 jaar |
Irene Kristiansen | F | - |
University of Bath
| 4 jaar |
Ibrahim Yousif Al-Hamoudi | M | - |
University of Bath
| 1 jaar |
Boon Chiang Boh | M | 61 |
University of Bath
| 2 jaar |
Alan Stuart-Grant | M | - |
University of Bath
| 4 jaar |
Norberto Whitaker Sobral Jannuzzi | M | 43 |
University of Bath
| 4 jaar |
Paul A. Barsanti | M | - |
University of Bath
| 3 jaar |
Tze Jye Sim | M | 43 |
University of Bath
| 4 jaar |
Yu Guan | F | 44 |
University of Bath
| 4 jaar |
Alistair Dunn-Coleman | M | - |
University of Bath
| 4 jaar |
Michael Pearson | M | 47 |
University of Bath
| 4 jaar |
Matt Stamp | M | - |
University of Bath
| 4 jaar |
Indy Johar | M | - |
University of Bath
| 6 jaar |
Hugh Owen | M | - |
University of Bath
| 4 jaar |
Vicki Caplan | F | - |
University of Bath
| 4 jaar |
Oliver Crouch | M | - |
University of Bath
| 4 jaar |
Kirsten Wolf | F | - |
University of Bath
| 4 jaar |
Hwa Sung Kwo | M | 52 |
University of Bath
| 2 jaar |
Stephen Endacott | M | - |
University of Bath
| 24 jaar |
Patrick Michael Reid | M | - |
University of Bath
| 4 jaar |
Will Rhind | M | 45 |
University of Bath
| 4 jaar |
Lise Kingo | F | 62 |
University of Bath
| 1 jaar |
Murtaza Raza | M | - |
University of Bath
| 1 jaar |
Simon Meyer | M | - |
University of Bath
| 4 jaar |
Graham David Harding | M | 58 |
University of Bath
| 2 jaar |
Laurence Ede | M | 52 |
University of Bath
| 2 jaar |
Richard Taylor | M | - |
University of Bath
| 4 jaar |
Peter Dowding | M | - |
University of Bath
| 1 jaar |
Sherief Bakr | M | - |
University of Bath
| 4 jaar |
Carlos Conti | M | - |
University of Bath
| 4 jaar |
Simon Hitchcock | M | 50 |
University of Bath
| 4 jaar |
Alan Rowsell | M | - |
University of Bath
| 4 jaar |
Norberto Whitaker Sobral Jannuzzi | M | 43 |
University of Bath
| 4 jaar |
Hock Beng Wong | M | 61 |
University of Bath
| 2 jaar |
Ping Keat Cheng | M | 64 |
University of Bath
| 2 jaar |
Andrew G. Charlesworth | M | - |
University of Bath
| 1 jaar |
Muhammed Wasif Ijlal | M | - |
University of Bath
| 2 jaar |
Kate Fry | F | - |
University of Bath
| 4 jaar |
Peng Sian Lee | M | 54 |
University of Bath
| 2 jaar |
Najla Al-Midfa | F | - |
University of Bath
| 3 jaar |
Duncan James Mackenzie Fergusson | M | - |
University of Bath
| 4 jaar |
Jonathan Buttigieg | M | - |
University of Bath
| 1 jaar |
Emma Knott | F | - |
University of Bath
| 4 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigd Koninkrijk | 45 | 88.24% |
Verenigde Staten | 6 | 11.76% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Andrew J. Geall
- Persoonlijk netwerk